Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: A 24-week follow-up study

Simple item page
dc.contributor.authorKotan, Vahap Ozan
dc.contributor.buuauthorKırhan, Emine
dc.contributor.buuauthorÖzkaya, Güven
dc.contributor.buuauthorKirli, Selçuk
dc.contributor.buuauthorSarandöl, Emre
dc.contributor.departmentUludağ Üniversitesi/ Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/ Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/ Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-2593-7196tr_TR
dc.contributor.orcid0000-0003-0297-846Xtr_TR
dc.contributor.researcheridABE-1716-2020tr_TR
dc.contributor.researcheridA-4421-2016tr_TR
dc.contributor.scopusid37104411100tr_TR
dc.contributor.scopusid16316866500tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.contributor.scopusid55943324800tr_TR
dc.date.accessioned2021-11-01T11:28:30Z
dc.date.available2021-11-01T11:28:30Z
dc.date.issued2011-07-19
dc.description.abstractPurpose: Major depressive disorder (MDD) is a devastating disease that afflicts large populations and has also been accepted to be an independent risk factor for cardiovascular disease (CVD). Oxidative stress seems to play an essential role in the relationship of MOD and CVD. We aimed to determine the level of oxidative stress in patients with MOD and to investigate the effects of long-term antidepressant (AD) treatment on the oxidative-antioxidative system parameters and CVD risk factors. Method: Fifty patients who fully met the fourth Diagnostic and Statistical Manual of Mental Disorders criteria for MOD and 44 healthy control subjects were included in the study. Control visits of the patients were repeated 6 weeks, 12 weeks and 24 weeks after beginning of the AD treatment Lipid profiles, oxidation and oxidizability of apolipoprotein B-containing lipoproteins (expressed as apo B-b-MDA and apo B-Delta-MDA, respectively), levels of plasma malondialdehyde (p-MDA), total antioxidative capacity (TAOC), antioxidant molecules and antioxidant enzyme activities including paraoxonase/arylesterase, red blood cell superoxide dismutase (RBC-SOD) and glutathione peroxidase were determined during 24-week of follow-up period. Results: According to the results of the study, p-MDA, apo B-b-MDA and RBC-SOD activity were increased and arylesterase activity was decreased in MDD patients. Body mass index (BMI), vitamin A and total cholesterol levels in MDD patients increased after 24-weeks of AD treatment RBC-SOD activity, TAOC, p-MDA and apo B-b-MDA levels were decreased: paraoxonase/arylesterase activities and apo B-Delta-MDA were increased at the end of 24th week. Conclusion: Oxidative stress, demonstrated in MDD patients, was partly improved during 24 weeks of AD treatment Increase in paraoxonase/arylesterase activities and decrease in p-MDA and apo B-b-MDA levels after 24 weeks seem to be beneficial for reduction of CVD risk in MDD patients. However increased BMI and apo B-Delta-MDA levels are negative cardiovascular effects of long-term AD treatment.en_US
dc.identifier.citationKotan, V. O. vd. (2011). “Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: A 24-week follow-up study”. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35(5), 1284-1290.en_US
dc.identifier.endpage1290tr_TR
dc.identifier.issn0278-5846
dc.identifier.issn1878-4216
dc.identifier.issue5tr_TR
dc.identifier.pubmed21515329tr_TR
dc.identifier.scopus2-s2.0-79957815233tr_TR
dc.identifier.startpage1284tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2011.03.021
dc.identifier.urihttp://hdl.handle.net/11452/22541
dc.identifier.volume35tr_TR
dc.identifier.wos000292470800013tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Scienceen_US
dc.relation.bap2008/37tr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalProgress in Neuro - Psychopharmacology & Biological Psychiatrytr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntioxidantsen_US
dc.subjectMajor depressive disorderen_US
dc.subjectMalondialdehydeen_US
dc.subjectOxidative stressen_US
dc.subjectCoronary-artery-diseaseen_US
dc.subjectLow-density-lipoproteinen_US
dc.subjectSuperoxide-dismutaseen_US
dc.subjectLipid-peroxidationen_US
dc.subjectAntioxidant statusen_US
dc.subjectNitric-oxideen_US
dc.subjectOxidized ldlen_US
dc.subjectRat-brainen_US
dc.subjectStressen_US
dc.subjectPlasmaen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.subject.emtreeAntidepressant agenten_US
dc.subject.emtreeApolipoprotein Ben_US
dc.subject.emtreeAryldialkylphosphataseen_US
dc.subject.emtreeArylesteraseen_US
dc.subject.emtreeCholesterolen_US
dc.subject.emtreeCitalopramen_US
dc.subject.emtreeEscitalopramen_US
dc.subject.emtreeFluoxetineen_US
dc.subject.emtreeGlutathione peroxidaseen_US
dc.subject.emtreeHigh density lipoprotein cholesterolen_US
dc.subject.emtreeMalonaldehydeen_US
dc.subject.emtreeMilnacipranen_US
dc.subject.emtreeMoclobemideen_US
dc.subject.emtreeParoxetineen_US
dc.subject.emtreeRetinolen_US
dc.subject.emtreeSertralineen_US
dc.subject.emtreeSuperoxide dismutaseen_US
dc.subject.emtreeTianeptineen_US
dc.subject.emtreeTriacylglycerolen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeCardiovascular risken_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiagnostic and statistical manual of mental disordersen_US
dc.subject.emtreeEnzyme activityen_US
dc.subject.emtreeErythrocyteen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLong term careen_US
dc.subject.emtreeMajor depressionen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeOxidationen_US
dc.subject.emtreeOxidative stressen_US
dc.subject.emtreeProtein expressionen_US
dc.subject.meshAdulten_US
dc.subject.meshAntidepressive agentsen_US
dc.subject.meshAntioxidantsen_US
dc.subject.meshApolipoproteinsen_US
dc.subject.meshAryldialkylphosphataseen_US
dc.subject.meshBlood cell counten_US
dc.subject.meshBody mass indexen_US
dc.subject.meshCarboxylic ester hydrolasesen_US
dc.subject.meshCardiovascular diseasesen_US
dc.subject.meshDepressive disorder majoren_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshHormonesen_US
dc.subject.meshHumansen_US
dc.subject.meshLipidsen_US
dc.subject.meshLiver function testsen_US
dc.subject.meshLong-term careen_US
dc.subject.meshMaleen_US
dc.subject.meshMalondialdehydeen_US
dc.subject.meshOxidative stressen_US
dc.subject.meshPsychiatric status rating scalesen_US
dc.subject.meshRisk factorsen_US
dc.subject.meshSuperoxide dismutaseen_US
dc.subject.meshYoung adulten_US
dc.subject.scopusSchizophrenia; Acetylcysteine; Bipolar Disorderen_US
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.titleEffects of long-term antidepressant treatment on oxidative status in major depressive disorder: A 24-week follow-up studyen_US
dc.typeArticle
dc.wos.quartileQ1 (Pharmacology & Pharmacy)en_US
dc.wos.quartileQ2en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus